NCT02212379 - Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

April 30, 2018

Conditions

HIV-1 Infection

Interventions

DRUG

raltegravir and etravirine

"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."

Trial Locations (19)

13009

Hôpital Sainte marguerite, Marseille

33076

Hôpital Saint André, Bordeaux

34000

Hôpital Gui de Chauliac, Montpellier

37044

Hôpital Bretonneau, Tours

44093

CHU Hôtel Dieu, Nantes

69317

Hôpital Croix Rousse, Lyon

75010

Hôpital Saint Louis, Paris

75013

Hôpital Pitié-Salpétrière, Paris

75014

Hôpital Cochin, Paris

75015

Hôpital Necker, Paris

75018

Hôpital Bichat Claude Bernard, Paris

75908

Hôpital Européen Georges Pompidou, Paris

93000

Hôpital Avicenne, Bobigny

93140

Hôpital Jean Verdier, Bondy

94275

Hôpital Bicêtre, Le Kremlin-Bicêtre

06202

Hôpital de l'Archet, Nice

08000

Hospital de Bellvitge, Barcelona

08025

Hospital de la santa Creu i San Pau, Barcelona

08036

Hospital Clinic, Barcelona

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV